Helomics® to Present at Biotech Showcase 2016 during the J. P. Morgan HealthCare Conference

PITTSBURGH--()--Helomics Corporation, a privately held comprehensive personalized healthcare company that develops innovative next generation diagnostics for the oncology field, announced today that it will present at the Biotech Showcase 2016 to be held January 11-13, 2016, at the Parc 55 San Francisco.

Neil Campbell, President and CEO of Helomics, will provide an overview of the Company’s personalized tumor profiling business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event:           Biotech Showcase 2016
Date: Tuesday, January 12, 2016
Time: 2:30pm (Pacific Time)
Location: Parc 55 San Francisco, Track E, Room Davidson

About Helomics® Corporation

Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a comprehensive personalized tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis to allow physicians to personally characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.

Contacts

Tiberend Strategic Advisors, Inc.
Investors
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire Sojda, 212-375-2686
csojda@tiberend.com